Theranostic gadolinium-based nanoparticles AGuIX®: in vivo imaging and safety evaluation - Université de Bourgogne Accéder directement au contenu
Communication Dans Un Congrès Année : 2015

Theranostic gadolinium-based nanoparticles AGuIX®: in vivo imaging and safety evaluation

Résumé

IntroductionA new efficient type of gadolinium (Gd)-based theranostic agent (AGuIX®) has recently been developed for MRI-guided radiotherapy.1 These nanoparticles consist of a polysiloxane network surrounded by Gd chelates. Nanoparticles, which contain high-Z contrast agents such as Gd-based nanoparticles, increase the sensitivity of the tumor to radiation. Owing to their small size (3 +/- 0.1 nm), AGuIX® typically exhibit biodistributions that are almost ideal for diagnostic and therapeutic purposes.2 Multi-imaging properties and safety evaluation of the Gd-based nanoparticles have been investigated before their clinical transfer. MethodsGd-based nanoparticles have been administrated to rats-bearing tumor and non-human primates for MRI and PET investigations. In parallel, regulatory investigations have been performed on both rodents and non-human primates.

Domaines

Cancer Imagerie
Fichier non déposé

Dates et versions

hal-01275107 , version 1 (16-02-2016)

Identifiants

  • HAL Id : hal-01275107 , version 1

Citer

Lucie Sancey, S. Kotb, J. Piraquive Agudelo, P. Bouziotis, F. Brunotte, et al.. Theranostic gadolinium-based nanoparticles AGuIX®: in vivo imaging and safety evaluation. 10th annual meeting of the European Society for Molecular Imaging (ESMI) - European Molecular Imaging Meeting (EMIM), Mar 2015, Tübingen, Germany. ⟨hal-01275107⟩
226 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More